본문 바로가기

추천 검색어

실시간 인기 검색어

학술논문

Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics

이용수 2

영문명
발행기관
대한신경정신의학회
저자명
JungSun Lee Seockhoon Chung JoonNoh Lee JunSoo Kwon DoHoon Kim ChulEung Kim KangSeob Oh YangWhan Jeo
간행물 정보
『Psychiatry Investigation』제7권 제3호, 189~195쪽, 전체 7쪽
주제분류
의약학 > 정신과학
파일형태
PDF
발행일자
2010.09.30
4,000

구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.

1:1 문의
논문 표지

국문 초록

영문 초록

Objective-To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). Methods-This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. Results-At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. Conclusion-This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.

목차

INTRODUCTION
METHODS
RESULTS
DISCUSSION
ACKNOWLEDGEMENTS
REFERENCES

키워드

해당간행물 수록 논문

참고문헌

교보eBook 첫 방문을 환영 합니다!

신규가입 혜택 지급이 완료 되었습니다.

바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!

교보e캐시 1,000원
TOP
인용하기
APA

JungSun Lee,Seockhoon Chung,JoonNoh Lee,JunSoo Kwon,DoHoon Kim,ChulEung Kim,KangSeob Oh,YangWhan Jeo. (2010).Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics. Psychiatry Investigation, 7 (3), 189-195

MLA

JungSun Lee,Seockhoon Chung,JoonNoh Lee,JunSoo Kwon,DoHoon Kim,ChulEung Kim,KangSeob Oh,YangWhan Jeo. "Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics." Psychiatry Investigation, 7.3(2010): 189-195

결제완료
e캐시 원 결제 계속 하시겠습니까?
교보 e캐시 간편 결제